Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 24, 2010

View Archived Issues

Promising phase I data on CAL-101 in hematological malignancies disclosed

Indian scientists claim new ketolides as antibacterial agents

Pfizer develops new glucocorticoid receptor agonists

Leo Pharma divulges new positive modulators of calcium-sensing receptor

New histamine H3 receptor antagonists presented by Evotec

Japan Tobacco patents new inhibitors of macrophage colony-stimulating factor 1 receptor

Sunesis begins phase III vosaroxin trial in acute myeloid leukemia

PTC Therapeutics completes enrollment of phase III Ataluren trial in cystic fibrosis

FDA grants orphan drug status to rFVIIIFc for hemophilia A treatment

VBL begins phase II study of VB-201 in patients with elevated hsCRP levels

AstraZeneca and Abbott discontinue development of Certriad for mixed dyslipidemia

Lentiviral vector-based vaccine VRX-1116 shows promise in HIV therapy

Lower risk of metabolic complications seen with darunavir vs. atazanavir plus ritonavir in HIV

TRPV4 antagonists hold promise for the treatment of bladder dysfunction

Combination of AZD-0530 and anastrozole shows promise in hormone receptor-positive breast cancer

Living Cell Technologies adds patients to Diabecell trial in New Zealand

FDA approves Amturnide, a triple-combination pill, to treat high blood pressure

Merck receives FDA approval for new indications for HPV vaccine Gardasil

FDA issues complete response letter for acetadote supplemental NDA

Gilead stops phase III trial of ambrisentan in IPF after interim analysis

Amylin and Lilly submit NDA for Byetta as an add-on therapy to basal insulin

Medicago provides phase II update on avian influenza vaccine

Intercell begins phase I trial of IC-84 against Clostridium difficile infections

Threshold reports phase I data for TH-302 in patients with advanced leukemia

Pfizer submits supplemental NDAs to FDA and EMA for Prevnar 13

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 9, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...